Publications Office of the EU
Suministro de Argipresina (DOE) - EU tenders
DisplayCustomHeader
MyPortal
Language Selector
English
BasketSummary
Procurement Detail Actions Portlet

Utilities

Procurement Detail Actions Portlet
OP Portal - Procurement - Details

Suministro de Argipresina (DOE)

Overview
  • Awarded
    25/06/2025
  • Today
    11/07/2025
Status
Awarded
Type of contract
Supplies
Subject for Renewal
Yes
Buyer
OSAKIDETZA - Servicio Vasco de Salud - OrganizaciĆ³n Central
Place of performance
NUTS code: Multiple place of performance
Location of buyer
NUTS code: ES211 Araba/Ɓlava
Business sector (Main CPV)
33600000 Pharmaceutical products
Total estimated contract value (excluding VAT)
Not available
Total final contract value (excluding VAT)
544,640.00 EUR
Procedure details
Tender reference number
2025/00617
Description

Suministro de Argipresina (DOE)

Submission Method
Not available
Tenders may be submitted
Not available
Information about a public contract, a framework agreement or a dynamic purchasing system (DPS)
Not available
Conditions for opening tenders (date)
Not available
Place of performance
ES EspaƱa
ES211 Araba/Ɓlava
CPV code

33600000 - Pharmaceutical products

Award method
Criterion:
Type: price
Description: Mejor precio
Weight (percentage, exact):
Estimated value
Not available
Final contracted value
544,640.00 EUR
Award of contract
Official name: AOP ORPHAN PHARMACEUTICALS IBERIA SL
Postal address:
Town: Rozas de Madrid, Las
Postal code: 28231
Country:
Documents
Prior information
Contract
Award
Footnote - legal notice

This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.